𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HIV-1 integrase inhibitors: 2003–2004 update

✍ Scribed by Raveendra Dayam; Jinxia Deng; Nouri Neamati

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
906 KB
Volume
26
Category
Article
ISSN
0198-6325

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this process provides an attractive strategy for antiviral drug design. The discovery of β‐diketo acid inhibitors played a major role in validating IN as a legitimate antiretroviral drug target. Over a decade of research, a plethora of IN inhibitors have been discovered and some showed antiviral activity consistent with their effect on IN. To date, at least two compounds have been tested in human but none are close to the FDA approval. In this review, we provide a comprehensive report of all small‐molecule IN inhibitors discovered during the years 2003 and 2004. Compilation of such data will prove beneficial in developing QSAR, virtual screening, pharmacophore hypothesis generation, and validation. © 2006 Wiley Periodicals, Inc. Med Res Rev

📜 SIMILAR VOLUMES

HIV-1 integrase inhibitors: 2005–2006 up
HIV-1 integrase inhibitors: 2005–2006 update
✍ Raveendra Dayam; Rambabu Gundla; Laith Q. Al-Mawsawi; Nouri Neamati 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 813 KB

## Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome, an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive strategy for antiretroviral drug design. Currently two IN inhibitors, MK‐0518 and GS‐9137, are in adva

HIV-1 integrase inhibitors: 2007–2008 up
HIV-1 integrase inhibitors: 2007–2008 update
✍ Kavya Ramkumar; Erik Serrao; Srinivas Odde; Nouri Neamati 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 892 KB

In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. T